P14 MIF IS AN ENDOGENOUS FIBROSIS LIMITING FACTOR IN PROGRESSIVE KIDNEY DISEASES  by Djudjaj, S. et al.
TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016Bhargava, V1, Rana, DS1, Jain, M2, Kumar, D3, Bhalla, AK1,
Gupta, A1, Gupta, A1, Malik, M1
1Sir Gangaram Hospital, Nephrology, New delhi, India; 2Sir Gangaram
Hospital, Genetic medicine, New delhi, India; 3Sir Gangaram Hospital,
Research Department, New delhi, India
Introduction: The clinical impact of anti-HLA antibodies is one of
the major area of research in renal allograft transplantation.
Luminex Platform has emerged as the favoured technology for
detection of HLA antibodies in addition to the CDC crossmatch
(XM). Luminex DSA crossmatch has been recently introduced in
India for detecting antibodies that are missed by CDC XM. We
present our experience with the Luminex based DSA crossmatch
test done in the recipients who underwent transplantation at Sir
Ganga Ram Hospital in the year 2013-14 with one year post
transplant follow up. The objective of the study was to evaluate the
impact of the pre-Tx DSAs detected by Luminex crossmatch on the
clinical outcome of the renal graft over a period of one year
Methods: We began performing DSA (donor speciﬁc antibody)
monitoring protocol by Luminex in the year 2013 at our center. The
present study includes patients from January 2013 to December
2013 with one year follow up post kidney transplant. Pre- trans-
plant sera from 46 renal transplant recipients with a negative CDC
crossmatch were assessed for donor-speciﬁc antibodies (DSA)
detection on Luminex Platform using Lifecodes DSA kit (Immucor).
The serum samples with DSA (HLA-Class I or II or both) of MFI
(mean ﬂuorescent intensity) value more than 500 was considered to
be positive. The results were then correlated with the clinical
outcomes of the renal allograft.
Results: SAs were found in 11 out of 46 recipients (23.9%). Of the
eleven DSA positive patients, 3 patients (27.27%) developed acute
graft rejection. All these 3 patients had positive C4d staining in
their biopsies and the MFI value of the DSA on Luminex platform
was found to be more than 1000. The remaining 8 DSA positive
patients showed no rejection and had stable graft function. The MFI
value of the DSAs in these patients ranged from 500-1000. All the
35 DSA negative patients (76.1%) were also having stable graft
function in one year follow up. Hence, AMR was more frequent in
the DSA positive group than in DSA negative group. outcome of the
renal graft over a period of one year.
Conclusions: The present study evaluates the importance of
Luminex DSA crossmatch test in detecting the donor speciﬁc HLA
antibodies over the CDC crossmatch. There was a higher incidence
of AMR in patients with pre-transplant DSA despite a negative CDC
crossmatch. The present study clearly establishes that the Luminex
DSA crossmatch is helpful for predicting post transplant graft
outcome or rejection. The laboratory cut off value of the MFI for
positive DSA was increased from 500 to 1000. We suggest that DSA
MFI value above 1000 should be considered for further evaluation
by Single antigen bead assay (SAB) by Luminex. However, the
clinical impact of the pre-Tx DSAs detected by Luminex techniques
has to be fully evaluated in terms of graft survival and more
retrospective studies with larger sample size.
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common end-point of progressive kidney diseases. A multitude of
factors and processes were found to promote and aggravate renal
ﬁbrosis, but our understanding of endogenous factors limiting
ﬁbrosis is limited.
Methods: Here we analyzed the role of macrophage migration
inhibitory factor (MIF), a pleiotropic proinﬂammatory cytokine, in
animal models of renal tubulointerstitial ﬁbrosis and inﬂammation.
Results: We show that MIF expression is reduced in murine and
human renal tubulointerstitial ﬁbrosis. MIF inhibition using gene
knock-out, neutralizing antibodies or a small-molecule inhibitor
aggravated ﬁbrosis and worsened parameters of renal function,
while treatment with murine recombinant MIF abrogated renal
ﬁbrosis. This effect was consistent in three distinct models of renal
ﬁbrosis, i.e. those induced by obstruction, ischemia-reperfusion or
toxin, and was also effective when treatment was initiated in
already established ﬁbrosis. Bone-marrow chimeras showed that
local but not bone-marrow derived MIF was involved. Mechanis-
tically, MIF reduced the expression of chemokine MCP-1 in tubular
cells and reduced renal inﬂammatory inﬁltrates already early in
disease.
Conclusions: Taken together, we identiﬁed a hitherto unappreci-
ated role of MIF as an endogenous factor limiting renal tubu-
lointerstitial ﬁbrosis via limiting renal inﬂammation. Our data raise
important safety concerns regarding the envisaged use of MIF in-
hibition as a treatment for inﬂammatory diseases.
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Introduction: MPO-ANCA-associated vasculitis (MPO-AAV) is a
systemic small vessel vasuculitis that involves preferentially the
kidneys. It has been shown the pathogenic role of MPO-ANCA in
MPO-AAV. Neutrophil extracellular traps (NETs), which are
released from neutrophils activated by microorganisms, are
composed of net-like chromatin ﬁbers and antimicrobial proteins,
such as MPO. The activated neutrophils die in due course with the
formation of NETs. During the NET formation, histones bound
chromatin ﬁbers are citrullinated by peptigylarginine deiminase 4
(PAD4), and consequently the chromatin ﬁbers are decondensated.
Thus, PAD4 plays a pivotal role in the NET formation. Although
NETs are essential for elimination of microorganisms, excessive
formation of NETs has been shown to be implicated in the MPO-
ANCA production. The aim of this study is to determine that in-
hibition of PAD4 can suppress the NET formation and MPO-ANCA
production in vivo.
Methods: According to our previous report, NETs were induced in
peripheral blood neutrophils derived from healthy donors (1106/
ml) by stimulation with 20 nM phorbol myristate acetate (PMA)
with or without 20 mM anti-thyroid drug, propylthiouracil (PTU)
for 2 hours at 37 oC. The effect of PAD4 inhibitor, 200 mM Cl-
amidine, on the in vitro NET formation induced by 20 nM PMAS7
